Pyruvate kinase deficiency is primarily caused by mutations in the PKLR gene, which encodes the pyruvate kinase enzyme found in red blood cells. These mutations follow an autosomal recessive inheritance pattern, which means both copies of the PKLR gene must be affected for an individual to have the condition. If a person inherits one mutated and one healthy copy, they are a carrier and typically do not experience symptoms, but they can pass the mutated copy on to their offspring. If both parents are carriers, there is a 25% chance with each pregnancy that the child will inherit two mutated copies and develop pyruvate kinase deficiency.

Introduction

Did you know that genetic factors are the root cause of certain types of persistent anaemia and that by learning about these genetic underpinnings, you could better understand your health status and options for support? Pyruvate kinase deficiency is an example of one such genetic condition that can lead to chronic haemolytic anaemia and a range of related symptoms. Learning about this can help you recognise symptoms and seek appropriate advice from a medical professional.

The main purpose of exploring the genetics of pyruvate kinase deficiency is to highlight how the autosomal recessive inheritance pattern works, why it is significant, and how it can affect families. This article aims to clarify the causes of pyruvate kinase deficiency, explain its inheritance, and identify potential steps for diagnosis and management. By the end, you should be better informed about how this condition arises and how genetic testing or counselling might assist in understanding your health risks.

What is Pyruvate Kinase deficiency?

Pyruvate kinase deficiency is a genetic condition that primarily affects red blood cells and results in chronic haemolytic anaemia, which refers to the premature destruction of these cells in the bloodstream. When red blood cells break down faster than they can be replaced, individuals can experience symptoms such as tiredness, jaundice, and shortness of breath. This deficiency is rare, but it is among the most common causes of non-spherocytic haemolytic anaemia in inherited conditions.

The role of the Pyruvate Kinase Enzyme

Pyruvate kinase is an important enzyme in glycolysis, the process by which glucose is converted into energy within cells. In red blood cells, glycolysis is the sole method of energy production because these cells lack the more common energy production component, mitochondria. When pyruvate kinase is deficient, red blood cells fail to generate sufficient energy, which makes them more fragile and prone to destruction. This leads to haemolytic anaemia because the red blood cells do not have a normal lifespan and the body struggles to replace them quickly enough.¹

Autosomal recessive inheritance

How autosomal recessive inheritance works

In autosomal recessive inheritance, a person must inherit two copies of a faulty gene (one from each parent) to display symptoms. If you have one defective gene and one healthy gene, you are considered a carrier. Carriers generally do not present with symptoms of the condition, but can pass the mutated gene on to their children. If two carriers have a child, each pregnancy has:

• A 25% chance of inheriting two mutated genes (the child will have the condition)
• A 50% chance of inheriting only one mutated gene (the child will be a carrier)
• A 25% chance of inheriting two healthy genes (the child will neither have the condition nor be a carrier)²

PKLR gene mutations

Pyruvate kinase deficiency is linked to mutations in the PKLR gene located on chromosome 1.³ When mutations occur in this gene, they disrupt the normal function or stability of the pyruvate kinase enzyme in red blood cells. This causes reduced production of adenosine triphosphate (ATP), the molecule that provides energy to cells. As a result, the red blood cells become less stable and are destroyed more rapidly than usual.

Clinical importance of autosomal recessive inheritance

The autosomal recessive pattern has implications for:

1. Family counselling: Families where one member is affected may benefit from genetic counselling to understand the risk of passing on or inheriting the condition.
2. Reproductive choices: Potential parents who are carriers can consider their reproductive options and discuss available interventions with healthcare professionals.
3. Detection of carriers: Identifying carriers in a family can help with early detection and management strategies, ensuring that children born with the condition can be supported promptly.⁴

Molecular mechanisms of Pyruvate Kinase deficiency

Red blood cell metabolism

Red blood cells rely on glycolysis for energy because they lack mitochondria. The final step in glycolysis involves converting phosphoenolpyruvate (PEP) to pyruvate, and pyruvate kinase catalyses this reaction. In pyruvate kinase deficiency, the catalytic capability of this enzyme is compromised, leading to reduced ATP levels inside the red blood cells. This low ATP level weakens cell membrane integrity and shortens the lifespan of red blood cells.³

Genetic variations within PKLR

Researchers have identified many different mutations in PKLR, and not all individuals with pyruvate kinase deficiency have the same mutation. Some mutations result in a complete loss of enzyme activity, while others allow for partial activity. The severity of symptoms usually corresponds to the degree of enzyme deficiency. In many cases, individuals with some residual enzyme activity have milder manifestations of the condition.³

Clinical features/symptoms

Haemolytic Anaemia and its consequences

Since pyruvate kinase deficiency causes excessive destruction of red blood cells, many clinical symptoms directly relate to haemolysis. Common manifestations include:

• Fatigue: Due to decreased oxygen delivery to tissues
• Jaundice: Due to increased bilirubin in response to red blood cell breakdown
• Splenomegaly (enlarged spleen): The spleen works overtime to filter out damaged red blood cells
• Gallstones: Excessive bilirubin can lead to pigment gallstone formation⁵

Neonatal jaundice

Newborns with pyruvate kinase deficiency often develop jaundice shortly after birth. This is because bilirubin levels (a by-product of red blood cell breakdown) rise quickly when the body destroys more red blood cells than normal. Although neonatal jaundice is relatively common in newborns, infants with pyruvate kinase deficiency may require extra treatment and monitoring to prevent complications.¹

Variable severity

Not everyone with pyruvate kinase deficiency has the same severity of symptoms. Some individuals are mildly affected and experience minimal difficulties, while others may require blood transfusions or splenectomy (removal of the spleen) to manage complications. These variations in severity can be influenced by the specific type of PKLR mutation and any co-existing genetic factors, as well as environmental and lifestyle factors.³

Diagnosis

Blood tests

Diagnosis typically involves blood tests to evaluate red blood cell function and identify the presence of haemolysis. Common investigations include:

1. Full blood count (FBC): May show a reduced haemoglobin level and other abnormalities in red blood cells
2. Reticulocyte count: Often elevated, indicating the body is trying to compensate for the loss of red blood cells
3. Bilirubin and lactate dehydrogenase (LDH) levels: Usually elevated in haemolysis

Pyruvate Kinase enzyme assay

A specific test known as a pyruvate kinase enzyme assay is used to measure the activity of the pyruvate kinase enzyme in the red blood cells. If enzyme activity is below normal levels, this may confirm pyruvate kinase deficiency.¹

Genetic testing

Molecular testing can pinpoint specific mutations in the PKLR gene. Identifying the exact mutation can help predict disease severity and guide management strategies. Genetic testing can also confirm carrier status for family members who want to know their risk of passing on the condition.⁶

Management and treatment

Supportive care

Supportive care is typically required to manage the symptoms of haemolysis. Individuals with pyruvate kinase deficiency may need:

• Folic acid supplementation: Folic acid can support red blood cell production
• Blood transfusions: In severe cases, transfusions can replace lost red blood cells and improve oxygen delivery
• Jaundice management: Phototherapy or other interventions can help newborns with high bilirubin levels

Splenectomy

Removing the spleen can reduce the destruction of red blood cells and may be considered if the individual experiences severe symptoms and frequent transfusions. However, splenectomy is usually reserved for cases where other treatments are not sufficient. Splenectomy involves risks, including a higher susceptibility to infections, and often requires immunisations against certain bacteria in advance.¹

Newborn management

Infants born with pyruvate kinase deficiency need close monitoring and may require treatments such as phototherapy to address elevated bilirubin levels. Early detection and intervention can help prevent complications like kernicterus, a condition in which high bilirubin levels damage the brain.¹

Future treatment prospects

Researchers are exploring potential new therapies, including gene therapy and targeted pharmaceuticals. Current clinical trials aim to find ways to replace the defective gene or enhance the function of the residual pyruvate kinase enzyme. While these treatments are under study, they could eventually offer a more definitive cure or improved symptom control.³

Genetic counselling

Genetic counselling is highly recommended for individuals with pyruvate kinase deficiency or those who are carriers, especially if they plan to have children. A genetic counsellor can:

1. Explain the autosomal recessive inheritance pattern and help you understand the risk of having an affected child
2. Provide information about prenatal diagnostic options, such as chorionic villus sampling or amniocentesis
3. Offer psychological support in adapting to a genetic diagnosis within the family

Genetic counselling also helps extended family members make informed decisions about genetic testing, family planning, and lifestyle considerations. It empowers individuals with the knowledge they need to take control of their health and well-being.⁴

FAQs

If I am a carrier of pyruvate kinase deficiency, will I have any symptoms?

Most carriers of autosomal recessive conditions, including pyruvate kinase deficiency, do not show any significant symptoms. However, they can still pass the mutated gene on to their offspring.

Can pyruvate kinase deficiency be cured?

Currently, there is no definitive cure, but treatments such as blood transfusions, splenectomy, and folic acid supplementation can help manage symptoms. Research is ongoing to explore the possibility of gene therapy in the future.

How common is pyruvate kinase deficiency?

It is considered a rare genetic disorder, although it is the most frequent cause of congenital non-spherocytic haemolytic anaemia. Exact prevalence figures can vary, but estimates suggest it affects individuals worldwide in varying degrees of severity.

Will my child have pyruvate kinase deficiency if both my partner and I are carriers?

Not necessarily. Each pregnancy has a 25% chance of resulting in a child with two mutated copies of the gene, a 50% chance of having a child who is a carrier, and a 25% chance of having a child with two healthy gene copies.

Summary

Pyruvate kinase deficiency is an inherited disorder that leads to chronic haemolytic anaemia due to diminished energy production in red blood cells. It is caused by mutations in the PKLR gene and follows an autosomal recessive inheritance pattern, which means two mutated copies of the PKLR gene are necessary for the condition to manifest. This pattern not only impacts the way the condition is passed down but also underscores the importance of carrier screening and genetic counselling for those who have a family history of pyruvate kinase deficiency. While treatment options focus on managing symptoms and complications, new therapeutic approaches, including gene therapy, are being studied for more definitive long-term control. By understanding the genetics and inheritance of pyruvate kinase deficiency, individuals and families can make informed decisions about testing, management, and family planning.